Hope Tribune

Psoriatic Arthritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Mylan, Celltrion, Pfizer, Amgen, CinnaGen, Biogen, UCB

 Breaking News
  • No posts were found

Psoriatic Arthritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Mylan, Celltrion, Pfizer, Amgen, CinnaGen, Biogen, UCB

October 31
22:02 2023
Psoriatic Arthritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Mylan, Celltrion, Pfizer, Amgen, CinnaGen, Biogen, UCB
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Psoriatic Arthritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Psoriatic Arthritis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Psoriatic Arthritis Market. 

The Psoriatic Arthritis Pipeline report embraces in-depth commercial, regulatory, and Psoriatic Arthritis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Psoriatic Arthritis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Psoriatic Arthritis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Psoriatic Arthritis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Psoriatic Arthritis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Psoriatic Arthritis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Psoriatic Arthritis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Psoriatic Arthritis therapeutic market.

Psoriatic Arthritis Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Psoriatic Arthritis. Currently, Abbvie is leading the therapeutics market with its Psoriatic Arthritis drug candidates in the most advanced stage of clinical development.

Psoriatic Arthritis Companies Actively Working in the Therapeutic Market Include:

Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cadilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu  Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and many others.

Emerging and Marketed Psoriatic Arthritis Drugs Covered in the Report Include:

  • ABT-494: AbbVie

  • Risankizumab: Abbvie

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Psoriatic Arthritis Companies Working in the Market @


Analysis of Emerging Psoriatic Arthritis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Intramuscular

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Psoriatic Arthritis Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Psoriatic Arthritis Treatment Patterns

4. Psoriatic Arthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Psoriatic Arthritis Late Stage Products (Phase-III)

7. Psoriatic Arthritis Mid-Stage Products (Phase-II)

8. Psoriatic Arthritis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriatic Arthritis Discontinued Products

13. Psoriatic Arthritis Product Profiles

14. Major Psoriatic Arthritis Companies in the Market

15. Key Products in the Psoriatic Arthritis Therapeutics Segment

16. Dormant and Discontinued Products

17. Psoriatic Arthritis Unmet Needs

18. Psoriatic Arthritis Future Perspectives

19. Psoriatic Arthritis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Bronchiectasis Market

“Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Bronchiectasis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Bronchiectasis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices